UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000041602 |
|---|---|
| Receipt number | R000047491 |
| Scientific Title | Clinical characteristics of primary aldosteronism and differences between primary aldosteronism and essential hypertension |
| Date of disclosure of the study information | 2020/08/29 |
| Last modified on | 2025/07/31 16:31:26 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Clinical characteristics of primary aldosteronism and differences between primary aldosteronism and essential hypertension
Acronym
Clinical characteristics of primary aldosteronism and differences between primary aldosteronism and essential hypertension
Scientific Title
Clinical characteristics of primary aldosteronism and differences between primary aldosteronism and essential hypertension
Scientific Title:Acronym
Clinical characteristics of primary aldosteronism and differences between primary aldosteronism and essential hypertension
Region
| Japan | Asia(except Japan) | Australia |
Condition
Condition
Primary aldosteronism
Classification by specialty
| Endocrinology and Metabolism |
Classification by malignancy
Others
Genomic information
YES
Objectives
Narrative objectives1
There are several types of primary aldosteronism, each with different clinical characteristics. The objective of this study is to clarify the clinical characteristics of each type of primary aldosteronism and the differences between primary aldosteronism and essential hypertension.
Moreover, since the diagnostic criteria for primary aldosteronism differ from country to country, the types of primary aldosteronism diagnosed also differ slightly. The purpose of this study is to determine the criteria that is more generalized by conducting international joint research.
Basic objectives2
Others
Basic objectives -Others
The analysis of proteins presumed to be involved in primary aldosteronism using archived samples, comprehensive protein profiling using omics platforms, and the measurement of non-coding RNA.
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
age, gender, blood pressure, BMI, blood tests (serum biochemistry test, daily fluctuation of hormones, etc.), urinalysis, confirmatory tests(captopril challenge test, furosemide and upright posture test, saline infusion test), contrast CT examination, adrenal vein sampling, portable polysomnography, ankle brachial pressure index, cardiac ultrasound, abdominal ultrasound, carotid ultrasound
Key secondary outcomes
Proteins presumed to be involved in primary aldosteronism, comprehensive protein profiling using omics platforms, and non-coding RNA
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Patients who were diagnosed with primary aldosteronism and essential hypertension at Nihon University Itabashi Hospital. (January 2006-July 21, 2025)
2. Patients who were diagnosed with primary aldosteronism and essential hypertension at Tokyo Medical and Dental University Hospital, Affiliated Hospital of Chongqing Medical University, Monash University, and Hudson Institute of Medical Research. (January 2006-July 21, 2025)
Key exclusion criteria
Patients who refused to participate in this study and the investigator determined to be unsuitable for study
Target sample size
1000
Research contact person
Name of lead principal investigator
| 1st name | Masanori |
| Middle name | |
| Last name | Abe |
Organization
Nihon University School of Medicine
Division name
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine
Zip code
173-8610
Address
30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo
TEL
+81-3-3972-8111
abe.masanori@nihon-u.ac.jp
Public contact
Name of contact person
| 1st name | Hiroki |
| Middle name | |
| Last name | Kobayashi |
Organization
Nihon University School of Medicine
Division name
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine
Zip code
173-8610
Address
30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo
TEL
+81-3-3972-8111
Homepage URL
kobayashi.hiroki@nihon-u.ac.jp
Sponsor or person
Institute
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
Institute
Department
Personal name
Funding Source
Organization
Division of Nephrology, Hypertension and Endocrinology, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Monash University,Hudson Institute of Medical Research, Monash Health, Chongqing Medical University
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Nihon university Itabashi hospital clinical reseach center
Address
30-1 Oyaguchi Kami-chou, Itabashi-ku, Tokyo
Tel
+81-3-3972-8111
med.itabashi.chiken@nihon-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 08 | Month | 29 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Open public recruiting
Date of protocol fixation
| 2020 | Year | 08 | Month | 29 | Day |
Date of IRB
| 2020 | Year | 08 | Month | 29 | Day |
Anticipated trial start date
| 2020 | Year | 08 | Month | 29 | Day |
Last follow-up date
| 2025 | Year | 07 | Month | 21 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
age, gender, blood pressure, BMI, blood tests (serum biochemistry test, daily fluctuation of hormones, etc.), urinalysis, confirmatory tests(captopril challenge test, furosemide and upright posture test, saline infusion test), contrast CT examination, adrenal vein sampling, portable polysomnography, ankle brachial pressure index, cardiac ultrasound, abdominal ultrasound, carotid ultrasound,proteins presumed to be involved in primary aldosteronism, comprehensive protein profiling using omics platforms, and non-coding RNA,etc.
Management information
Registered date
| 2020 | Year | 08 | Month | 29 | Day |
Last modified on
| 2025 | Year | 07 | Month | 31 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047491
